Literature DB >> 17223347

High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Lakshmi Galam1, M Kyle Hadden, Zeqiang Ma, Qi-Zhuang Ye, Bo-Geon Yun, Brian S J Blagg, Robert L Matts.   

Abstract

Previously, we have demonstrated that the renaturation of heat denatured firefly luciferase is dependent upon the activity of Hsp90 in rabbit reticulocyte lysate. Here, we demonstrate that this assay may identify inhibitors that obstruct the chaperone activity of Hsp90 either by direct binding to its N-terminal or C-terminal nucleotide binding sites or by interference with the ability of the chaperone to switch conformations. The assay was adapted and optimized for high-throughput screening. Greater than 20,000 compounds were screened to demonstrate the feasibility of using this assay on a large scale. The assay was reproducible (av Z-factor=0.62) and identified 120 compounds that inhibited luciferase renaturation by greater than 70% at a concentration of 12.5 microg/mL. IC50 values for twenty compounds with varying structures were determined for inhibition of luciferase refolding and in cell-based assays for Hsp90 inhibition. Several compounds had IC50 values <10 microM and represent a number of new lead structures with the potential for further development and optimization as potent Hsp90 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223347      PMCID: PMC1906718          DOI: 10.1016/j.bmc.2007.01.004

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  42 in total

1.  The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes.

Authors:  J P Grenert; B D Johnson; D O Toft
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

2.  Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence.

Authors:  T Scheibel; T Weikl; J Buchner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Hop modulates Hsp70/Hsp90 interactions in protein folding.

Authors:  B D Johnson; R J Schumacher; E D Ross; D O Toft
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

4.  Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone.

Authors:  C Prodromou; S M Roe; R O'Brien; J E Ladbury; P W Piper; L H Pearl
Journal:  Cell       Date:  1997-07-11       Impact factor: 41.582

5.  Cooperative action of Hsp70, Hsp90, and DnaJ proteins in protein renaturation.

Authors:  R J Schumacher; W J Hansen; B C Freeman; E Alnemri; G Litwack; D O Toft
Journal:  Biochemistry       Date:  1996-11-26       Impact factor: 3.162

6.  Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.

Authors:  C E Stebbins; A A Russo; C Schneider; N Rosen; F U Hartl; N P Pavletich
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

7.  Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates.

Authors:  S D Hartson; V Thulasiraman; W Huang; L Whitesell; R L Matts
Journal:  Biochemistry       Date:  1999-03-23       Impact factor: 3.162

8.  ATP-dependent chaperoning activity of reticulocyte lysate.

Authors:  R J Schumacher; R Hurst; W P Sullivan; N J McMahon; D O Toft; R L Matts
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

9.  Evidence that Hsc70 negatively modulates the activation of the heme-regulated eIF-2alpha kinase in rabbit reticulocyte lysate.

Authors:  V Thulasiraman; Z Xu; S Uma; Y Gu; J J Chen; R L Matts
Journal:  Eur J Biochem       Date:  1998-08-01

Review 10.  Inhibitors of the HSP90 molecular chaperone: current status.

Authors:  Swee Sharp; Paul Workman
Journal:  Adv Cancer Res       Date:  2006       Impact factor: 6.242

View more
  27 in total

1.  The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.

Authors:  Haihao Zhu; Steve Woolfenden; Roderick T Bronson; Zahara M Jaffer; Sofia Barluenga; Nicolas Winssinger; Allan E Rubenstein; Ruihong Chen; Al Charest
Journal:  Mol Cancer Ther       Date:  2010-07-19       Impact factor: 6.261

2.  Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells.

Authors:  M Kyle Hadden; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2007-07-13       Impact factor: 2.823

Review 3.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

4.  Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Authors:  Takrima Sadikot; Megan Swink; Jeffery D Eskew; Douglas Brown; Huiping Zhao; Bhaskar R Kusuma; Roger A Rajewski; Brian S J Blagg; Robert L Matts; Jeffrey M Holzbeierlein; George A Vielhauer
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

5.  Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.

Authors:  Jason Gavenonis; Nicholas E Jonas; Joshua A Kritzer
Journal:  Bioorg Med Chem       Date:  2014-06-14       Impact factor: 3.641

6.  Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40.

Authors:  Susanne Wisén; Eric B Bertelsen; Andrea D Thompson; Srikanth Patury; Peter Ung; Lyra Chang; Christopher G Evans; Gladis M Walter; Peter Wipf; Heather A Carlson; Jeffrey L Brodsky; Erik R P Zuiderweg; Jason E Gestwicki
Journal:  ACS Chem Biol       Date:  2010-06-18       Impact factor: 5.100

7.  Gambogic acid, a natural product inhibitor of Hsp90.

Authors:  Jason Davenport; Jacob R Manjarrez; Laura Peterson; Brian Krumm; Brian S J Blagg; Robert L Matts
Journal:  J Nat Prod       Date:  2011-04-12       Impact factor: 4.050

8.  Monitoring of the Heat Shock Response with a Real-Time Luciferase Reporter.

Authors:  Toshiki Kijima; Takanori Eguchi; Len Neckers; Thomas L Prince
Journal:  Methods Mol Biol       Date:  2018

Review 9.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.

Authors:  Len Neckers; Brian Blagg; Timothy Haystead; Jane B Trepel; Luke Whitesell; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2018-02-01       Impact factor: 3.667

10.  Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.

Authors:  Suman Ghosh; Yang Liu; Gaurav Garg; Mercy Anyika; Nolan T McPherson; Jiacheng Ma; Rick T Dobrowsky; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.